Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04061811

Acronym

SONGBIRD

Enrollment

153

Registered

2019-08-20

Start date

2018-08-01

Completion date

2019-02-28

Last updated

2019-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Heart Failure

Keywords

congestive heart failure (HF), biomarker, chronic kidney disease (CKD), hemodialysis (HD), peritoneal dialysis (PD), neprilysin (NEP), growth differentiation factor-15 (GDF15)

Brief summary

Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis. Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts. Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP activity in patients on chronic dialysis without and with HF, as diagnosed by clinical parameters and post-dialysis echocardiography. We use correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses.

Interventions

DIAGNOSTIC_TESTDiagnostic biomarker study

Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months

Exclusion criteria

* previous switch of the type of renal replacement therapy from HD to PD or vice versa * age \<18 years * pregnancy * plasma exchange or apheresis in the past 6 months * unipolar pacemaker * history of whole extremity amputation

Design outcomes

Primary

Measure	Time frame	Description
HF diagnosis	Baseline (at study entry (diagnostic biomarker study))	Diagnosis of HF

Countries

France, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026